Bioenergetics

SS-31 research overview

A mitochondria-targeting tetrapeptide studied for its interaction with cardiolipin in inner-membrane research models.

FOR RESEARCH USE ONLY

This product is intended exclusively for laboratory research purposes. It is not intended for human or veterinary use, consumption, administration, diagnosis, treatment, prevention, or cure of any disease or condition.

Sequence
D-Arg-2′,6′-Dmt-Lys-Phe-NH₂
Molecular weight
639.79 g/mol
CAS
736992-21-5
Research category
Bioenergetics

Compound identity and classification

SS-31 is classified as: Cardiolipin-binding aromatic-cationic tetrapeptide.

SS-31 is a four-residue aromatic-cationic peptide containing D-arginine and dimethyltyrosine. Its alternating charge and aromatic pattern is the structural basis for the membrane-association behavior described in the literature.

General research background

Published laboratory work places SS-31 within the Szeto-Schiller peptide series developed for mitochondrial research. Reported studies are in isolated mitochondria, cell culture, and preclinical animal models.

Molecular and biological pathways under investigation

The pathway under investigation is association with cardiolipin in the inner mitochondrial membrane, with downstream measures including cristae morphology, electron transport chain efficiency, and reactive oxygen species generation.

Areas of laboratory research

Reported laboratory work with this material clusters into the following areas. Listing an area describes where research activity exists, not an established result.

  • Isolated mitochondria respirometry
  • Cardiolipin binding and membrane-interaction assays
  • Reactive oxygen species and redox-state measurement
  • Cristae ultrastructure imaging studies

Analytical documentation

ATMI Labs publishes the identity and purity documentation supplied for each released lot. Any purity figure shown comes from the report filed for that specific batch rather than from a general catalog claim.

Research limitations

Published work involving SS-31 is largely confined to in vitro systems and preclinical animal models. Findings in those systems do not establish effects in humans, and model-to-model variability in preparation, vehicle, and endpoint selection limits direct comparison between studies.

Analytical purity describes the material, not biological activity. Laboratories should design their own controls, and treat any pathway description as a hypothesis under investigation rather than an established result.

Handling and laboratory considerations

Lyophilized research materials are handled as temperature-sensitive laboratory chemicals. Storage temperature, reconstitution solvent, container choice, and stability windows are determined by the receiving laboratory's written protocol.

Every ATMI Labs lot is released with batch documentation so identity and purity figures used in a study can be traced back to the specific lot in hand.

  • Confirm the lot identifier on the vial label against the published quality record.
  • Record lot, strength, and receipt date in the laboratory inventory before use.
  • Follow institutional handling, labeling, and disposal procedures for research chemicals.

References and scientific sources

ATMI Labs does not summarize or reinterpret individual studies on this page. Laboratories designing work with this material are expected to consult the primary literature directly.

  • PubMed / MEDLINE (National Library of Medicine) for peer-reviewed primary literature.
  • PubChem and ChEMBL for chemical identity, structure, and physicochemical records.
  • UniProt for sequence and receptor/target annotation where a protein target applies.
  • The lot-specific quality record published by ATMI Labs for analytical identity and purity.

Research use scope

SS-31 supplied by ATMI Labs is sold exclusively for laboratory research and analytical purposes. It is not a drug, supplement, cosmetic, or food, and it is not intended for human or veterinary use.

Nothing on this page describes therapeutic use, dosing, or clinical outcomes. Literature referenced in general terms describes laboratory and preclinical model systems only.

Lab specifications, released lots, and availability for this compound live on its catalog page.

More research overviews